Which has preferable earnings and valuation, CLRB or TELO?

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A Telomir Pharmaceuticals N/A N/A -$10.41M -$0.29 N/A

Is CLRB or TELO more profitable?

Telomir Pharmaceuticals' return on equity of -201.23% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Cellectar Biosciences N/A -349.24% -153.18% Telomir Pharmaceuticals N/A -201.23% -172.71%

Do analysts recommend THAR or CLRB?

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 316.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Tharimmune. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tharimmune 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Cellectar Biosciences 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.80

Which has stronger valuation & earnings, THAR or CLRB?

Tharimmune is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Tharimmune N/A N/A -$12.20M -$3.99 N/A Cellectar Biosciences N/A N/A -$21.79M -$6.66 N/A

Is THAR or CLRB more profitable?

Cellectar Biosciences' return on equity of -349.24% beat Tharimmune's return on equity. Company Net Margins Return on Equity Return on Assets Tharimmune N/A -588.45% -264.41% Cellectar Biosciences N/A -349.24% -153.18%

Is GANX or CLRB more profitable?

Gain Therapeutics' return on equity of -201.44% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Gain Therapeutics N/A -201.44% -136.24% Cellectar Biosciences N/A -349.24% -153.18%

Does the media refer more to GANX or CLRB?

In the previous week, Cellectar Biosciences had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Gain Therapeutics. Cellectar Biosciences' average media sentiment score of 0.50 beat Gain Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gain Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is FRMM or CLRB more profitable?

Forum Markets' return on equity of -242.09% beat Cellectar Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Forum Markets N/A -242.09% -135.46% Cellectar Biosciences N/A -349.24% -153.18%

Does the media prefer FRMM or CLRB?

In the previous week, Cellectar Biosciences had 3 more articles in the media than Forum Markets. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Forum Markets. Cellectar Biosciences' average media sentiment score of 0.50 beat Forum Markets' score of 0.34 indicating that Cellectar Biosciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forum Markets 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor CLRB or ATRA?

In the previous week, Cellectar Biosciences had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.84 beat Cellectar Biosciences' score of 0.50 indicating that Atara Biotherapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cellectar Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Atara Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Cellectar Biosciences (CLRB) Competitors

$2.64 -0.02 (-0.83%)

As of 12:44 PM Eastern

Compare

CLRB vs. TELO, THAR, GANX, FRMM, and ATRA

Should you buy Cellectar Biosciences stock or one of its competitors? MarketBeat compares Cellectar Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Cellectar Biosciences include Telomir Pharmaceuticals (TELO), Tharimmune (THAR), Gain Therapeutics (GANX), Forum Markets (FRMM), and Atara Biotherapeutics (ATRA).

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Cellectar Biosciences (NASDAQ:CLRB) and Telomir Pharmaceuticals (NASDAQ:TELO) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Cellectar Biosciences currently has a consensus target price of $11.00, suggesting a potential upside of 316.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe Cellectar Biosciences is more favorable than Telomir Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Telomir Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

16.4% of Cellectar Biosciences shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 16.4% of Telomir Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market. Comparatively, Telomir Pharmaceuticals has a beta of -0.24, indicating that its stock price is 124% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 4 more articles in the media than Telomir Pharmaceuticals. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Telomir Pharmaceuticals. Cellectar Biosciences' average media sentiment score of 0.50 beat Telomir Pharmaceuticals' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the media.

Company	Overall Sentiment
Cellectar Biosciences	Neutral
Telomir Pharmaceuticals	Neutral

Telomir Pharmaceuticals is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Telomir Pharmaceuticals	N/A	N/A	-$10.41M	-$0.29	N/A

Telomir Pharmaceuticals' return on equity of -201.23% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Telomir Pharmaceuticals	N/A	-201.23%	-172.71%

Summary

Cellectar Biosciences beats Telomir Pharmaceuticals on 10 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Tharimmune?

Tharimmune (NASDAQ:THAR) and Cellectar Biosciences (NASDAQ:CLRB) are related small-cap companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, earnings, profitability, analyst recommendations, risk, media sentiment, institutional ownership and valuation.

Cellectar Biosciences' return on equity of -349.24% beat Tharimmune's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tharimmune	N/A	-588.45%	-264.41%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Cellectar Biosciences has a consensus target price of $11.00, indicating a potential upside of 316.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Tharimmune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tharimmune	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

In the previous week, Cellectar Biosciences had 4 more articles in the media than Tharimmune. MarketBeat recorded 4 mentions for Cellectar Biosciences and 0 mentions for Tharimmune. Cellectar Biosciences' average media sentiment score of 0.50 beat Tharimmune's score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Tharimmune	Neutral
Cellectar Biosciences	Neutral

1.2% of Tharimmune shares are held by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are held by institutional investors. 6.7% of Tharimmune shares are held by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Tharimmune has a beta of 1.43, indicating that its share price is 43% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

Tharimmune is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tharimmune	N/A	N/A	-$12.20M	-$3.99	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Summary

Cellectar Biosciences beats Tharimmune on 10 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Gain Therapeutics?

Gain Therapeutics (NASDAQ:GANX) and Cellectar Biosciences (NASDAQ:CLRB) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

In the previous week, Cellectar Biosciences had 3 more articles in the media than Gain Therapeutics. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Gain Therapeutics. Cellectar Biosciences' average media sentiment score of 0.50 beat Gain Therapeutics' score of 0.00 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Gain Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Gain Therapeutics has a beta of 0.19, indicating that its share price is 81% less volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market.

12.0% of Gain Therapeutics shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 4.2% of Gain Therapeutics shares are owned by company insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Gain Therapeutics has higher revenue and earnings than Cellectar Biosciences. Gain Therapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Gain Therapeutics	$50K	1,480.81	-$20.16M	-$0.58	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

Gain Therapeutics presently has a consensus price target of $7.50, suggesting a potential upside of 332.03%. Cellectar Biosciences has a consensus price target of $11.00, suggesting a potential upside of 316.98%. Given Gain Therapeutics' higher possible upside, analysts plainly believe Gain Therapeutics is more favorable than Cellectar Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Gain Therapeutics	1 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.67
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Gain Therapeutics' return on equity of -201.44% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Gain Therapeutics	N/A	-201.44%	-136.24%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Gain Therapeutics beats Cellectar Biosciences on 8 of the 15 factors compared between the two stocks.

How does Cellectar Biosciences compare to Forum Markets?

Forum Markets (NASDAQ:FRMM) and Cellectar Biosciences (NASDAQ:CLRB) are related small-cap companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation, media sentiment and analyst recommendations.

Forum Markets presently has a consensus target price of $10.00, suggesting a potential upside of 81.62%. Cellectar Biosciences has a consensus target price of $11.00, suggesting a potential upside of 316.98%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, analysts plainly believe Cellectar Biosciences is more favorable than Forum Markets.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forum Markets	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.50
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80

Forum Markets has a beta of 1.38, indicating that its stock price is 38% more volatile than the broader market. Comparatively, Cellectar Biosciences has a beta of 0.55, indicating that its stock price is 45% less volatile than the broader market.

In the previous week, Cellectar Biosciences had 3 more articles in the media than Forum Markets. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Forum Markets. Cellectar Biosciences' average media sentiment score of 0.50 beat Forum Markets' score of 0.34 indicating that Cellectar Biosciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forum Markets	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Cellectar Biosciences has lower revenue, but higher earnings than Forum Markets. Cellectar Biosciences is trading at a lower price-to-earnings ratio than Forum Markets, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forum Markets	$6.55M	11.26	-$450.52M	-$36.07	N/A
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A

4.1% of Forum Markets shares are owned by institutional investors. Comparatively, 16.4% of Cellectar Biosciences shares are owned by institutional investors. 25.2% of Forum Markets shares are owned by insiders. Comparatively, 2.6% of Cellectar Biosciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Forum Markets' return on equity of -242.09% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forum Markets	N/A	-242.09%	-135.46%
Cellectar Biosciences	N/A	-349.24%	-153.18%

Summary

Cellectar Biosciences beats Forum Markets on 8 of the 14 factors compared between the two stocks.

How does Cellectar Biosciences compare to Atara Biotherapeutics?

Cellectar Biosciences (NASDAQ:CLRB) and Atara Biotherapeutics (NASDAQ:ATRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their media sentiment, profitability, valuation, institutional ownership, analyst recommendations, earnings, risk and dividends.

Atara Biotherapeutics has higher revenue and earnings than Cellectar Biosciences. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Cellectar Biosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cellectar Biosciences	N/A	N/A	-$21.79M	-$6.66	N/A
Atara Biotherapeutics	$23.14M	3.38	$32.69M	-$0.67	N/A

Cellectar Biosciences currently has a consensus price target of $11.00, suggesting a potential upside of 316.98%. Atara Biotherapeutics has a consensus price target of $9.50, suggesting a potential upside of 9.32%. Given Cellectar Biosciences' stronger consensus rating and higher possible upside, research analysts clearly believe Cellectar Biosciences is more favorable than Atara Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cellectar Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Atara Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Cellectar Biosciences had 3 more articles in the media than Atara Biotherapeutics. MarketBeat recorded 4 mentions for Cellectar Biosciences and 1 mentions for Atara Biotherapeutics. Atara Biotherapeutics' average media sentiment score of 0.84 beat Cellectar Biosciences' score of 0.50 indicating that Atara Biotherapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Cellectar Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Atara Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Cellectar Biosciences has a beta of 0.55, indicating that its share price is 45% less volatile than the broader market. Comparatively, Atara Biotherapeutics has a beta of 0.08, indicating that its share price is 92% less volatile than the broader market.

16.4% of Cellectar Biosciences shares are owned by institutional investors. Comparatively, 70.9% of Atara Biotherapeutics shares are owned by institutional investors. 2.6% of Cellectar Biosciences shares are owned by insiders. Comparatively, 41.2% of Atara Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Cellectar Biosciences has a net margin of 0.00% compared to Atara Biotherapeutics' net margin of -40.91%. Atara Biotherapeutics' return on equity of -79.12% beat Cellectar Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cellectar Biosciences	N/A	-349.24%	-153.18%
Atara Biotherapeutics	-40.91%	-79.12%	-35.29%

Summary

Cellectar Biosciences and Atara Biotherapeutics tied by winning 8 of the 16 factors compared between the two stocks.

Get Cellectar Biosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLRB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLRB vs. The Competition

Export

Metric	Cellectar Biosciences	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$20.93M	$11.50B	$6.81B	$12.94B
Dividend Yield	N/A	2.74%	2.60%	10.03%
P/E Ratio	-0.39	791.51	279.92	25.45
Price / Sales	N/A	943.66	647.84	115.11
Price / Cash	N/A	14.82	28.64	34.82
Price / Book	1.40	10.39	11.11	6.33
Net Income	-$21.79M	$2.80B	$3.48B	$347.60M
7 Day Performance	5.52%	1.61%	2.04%	2.78%
1 Month Performance	-6.12%	-3.16%	-3.16%	-2.36%
1 Year Performance	-47.87%	155.11%	63.65%	20.74%

Cellectar Biosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLRB Cellectar Biosciences	3.844 of 5 stars	$2.64 -0.8%	$11.00 +317.0%	-43.6%	$20.93M	N/A	N/A	10
TELO Telomir Pharmaceuticals	0.1485 of 5 stars	$1.15 -6.5%	N/A	-29.5%	$79.09M	N/A	N/A	1	Positive News Gap Down
THAR Tharimmune	N/A	$2.03 +4.6%	N/A	+55.6%	$76.59M	N/A	N/A	2	Positive News Gap Up
GANX Gain Therapeutics	1.9733 of 5 stars	$1.73 -7.2%	$7.50 +334.3%	+21.5%	$73.66M	N/A	N/A	20	News Coverage Positive News Upcoming Earnings
FRMM Forum Markets	3.5481 of 5 stars	$5.27 -4.8%	$10.00 +89.6%	N/A	$70.62M	$6.55M	N/A	7

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLRB) was last updated on 8/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Cellectar Biosciences (CLRB) Competitors

CLRB vs. TELO, THAR, GANX, FRMM, and ATRA

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Summary

How does Cellectar Biosciences compare to Tharimmune?

Summary

How does Cellectar Biosciences compare to Gain Therapeutics?

Summary

How does Cellectar Biosciences compare to Forum Markets?

Summary

How does Cellectar Biosciences compare to Atara Biotherapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Cellectar Biosciences (CLRB) Competitors

CLRB vs. TELO, THAR, GANX, FRMM, and ATRA

How does Cellectar Biosciences compare to Telomir Pharmaceuticals?

Do analysts recommend CLRB or TELO?

Do insiders & institutionals have more ownership in CLRB or TELO?

Which has more risk & volatility, CLRB or TELO?

Does the media refer more to CLRB or TELO?

Which has preferable earnings and valuation, CLRB or TELO?

Is CLRB or TELO more profitable?

Summary

How does Cellectar Biosciences compare to Tharimmune?

Is THAR or CLRB more profitable?

Do analysts recommend THAR or CLRB?

Does the media refer more to THAR or CLRB?

Do insiders and institutionals believe in THAR or CLRB?

Which has more risk and volatility, THAR or CLRB?

Which has stronger valuation & earnings, THAR or CLRB?

Summary

How does Cellectar Biosciences compare to Gain Therapeutics?

Does the media refer more to GANX or CLRB?

Which has more risk & volatility, GANX or CLRB?

Do institutionals and insiders have more ownership in GANX or CLRB?

Which has higher valuation & earnings, GANX or CLRB?

Do analysts prefer GANX or CLRB?

Is GANX or CLRB more profitable?

Summary

How does Cellectar Biosciences compare to Forum Markets?

Do analysts prefer FRMM or CLRB?

Which has more volatility and risk, FRMM or CLRB?

Does the media prefer FRMM or CLRB?

Which has stronger valuation and earnings, FRMM or CLRB?

Do insiders & institutionals hold more shares of FRMM or CLRB?

Is FRMM or CLRB more profitable?

Summary

How does Cellectar Biosciences compare to Atara Biotherapeutics?

Which has stronger valuation and earnings, CLRB or ATRA?

Do analysts rate CLRB or ATRA?

Does the media favor CLRB or ATRA?

Which has more risk and volatility, CLRB or ATRA?

Do insiders & institutionals believe in CLRB or ATRA?

Is CLRB or ATRA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLRB vs. The Competition

Cellectar Biosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools